

March 24, 2021

# Perimeter Medical Imaging AI to Present at Lytham Partners Spring 2021 Investor Conference

***Company Presentation at 2:45 p.m. ET on Tuesday, March 30, 2021***

TORONTO--(BUSINESS WIRE)-- Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need, today announced that Jeremy Sobotta, Perimeter’s Chief Executive Officer, will present a company overview at the Lytham Partners Spring 2021 Investor Conference on Tuesday, March 30, 2021 at 2:45 p.m. ET.

A link to the live webcast of the presentation will be available on Perimeter’s website at <https://ir.perimetermed.com> or at <https://www.webcaster4.com/Webcast/Page/2650/40344>. The webcast will also be archived and available for replay following the event.

Management will also be participating in virtual one-on-one meetings throughout the event, which run from March 30, 2021 through April 1, 2021. To arrange a meeting, please contact Lytham Partners at [1x1@lythampartners.com](mailto:1x1@lythampartners.com) or register [here](#).

## **About Perimeter Medical Imaging AI, Inc.**

Perimeter Medical Imaging AI (TSX-V:PINK)(OTC:PYNKF)(FSE:4PC) is a Toronto-based company with U.S. headquarters in Dallas, Texas that is developing, with plans to commercialize, advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. Perimeter’s OCT Imaging platform is a point-of-care imaging system that provides clinicians with real-time, ultra-high-resolution, sub-surface image volumes of the margin (1-2 mm below the surface) of an excised tissue specimen. The ability to visualize microscopic tissue structures during a clinical procedure in addition to standard of care tissue assessment for decision making during the procedure has the potential to result in better long-term outcomes for patients and lower costs to the healthcare system. Perimeter’s OCT Imaging platform is cleared by the FDA as an imaging tool in the evaluation of excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest. In addition, Perimeter is developing advanced artificial intelligence/machine learning image assessment tools intended to increase the efficiency of review.

Perimeter’s ticker symbol “PINK” is a reference to the pink ribbons used during Breast Cancer Awareness Month by the Canadian Cancer Society and the American Cancer Society, driving home the company’s dedication to helping surgeons, radiologists and pathologists use Perimeter’s imaging technology and AI (Artificial Intelligence) in the fight against breast cancer, which is estimated to [account for 30%](#) of all female cancer diagnoses

this year.

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20210324005924/en/>

Jodi Regts

Corporate Communications / Investor Relations

Perimeter Medical Imaging AI, Inc.

+1 778-999-5634

[media@perimetermed.com](mailto:media@perimetermed.com)

Ben Shamsian or Joe Dorame

Lytham Partners, LLC

Direct: 646-829-9701

Main: 602 889 9700

[PINK@lythampartners.com](mailto:PINK@lythampartners.com)

Source: Perimeter Medical Imaging AI, Inc.